TCI GENE Inc. (TPEX:6879)
35.55
0.00 (0.00%)
Aug 26, 2026, 12:47 PM CST
TCI GENE Revenue
TCI GENE had revenue of 131.90M TWD in the half year ending December 31, 2025, a decrease of -28.31%. This brings the company's revenue in the last twelve months to 251.39M, down -22.59% year-over-year. In the year 2025, TCI GENE had annual revenue of 273.61M, down -21.27%.
Revenue (ttm)
251.39M
Revenue Growth
-22.59%
P/S Ratio
3.74
Revenue / Employee
n/a
Employees
n/a
Market Cap
940.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 273.61M | -73.93M | -21.27% |
| Dec 31, 2024 | 347.54M | 13.68M | 4.10% |
| Dec 31, 2023 | 333.86M | -90.17M | -21.26% |
| Dec 31, 2022 | 424.02M | -8.20M | -1.90% |
| Dec 31, 2021 | 432.22M | 239.27M | 124.01% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 709.37M |
| Meribank Biotech | 408.48M |
| BioLASCO Taiwan | 258.04M |
| GeneReach Biotechnology | 238.08M |
| NatureWise Biotech & Medicals | 174.62M |
| Lukas Biomedical | 170.01M |
| Holy Stone Healthcare | 47.51M |
| SynCore Biotechnology Co.,Ltd | 26.24M |